FOLH1 and central nervous system cancer: About 1/3 of the grade I (31.7%, 13/28) and II tumours (32.6%, 15/31) showed PSMA expression in tumour cells, whereas 56% (14/11) of grade III and 44.7% (116/143) of grade IV gliomas (Table 2) expressed PSMA in tumour cells.